Oxford Immunotec prices IPO below the range at $12, raising $64 million

By
A A A
Share |

Oxford Immunotec Global, which sells diagnostic tests for latent tuberculosis infection (LTBI), raised $64 million by offering 5.4 million shares (all primary) at $12, below the range of $13 to $15. Oxford, which initially filed confidentially on 9/10/2013, plans to list on the NASDAQ under the symbol "OXFD". J.P. Morgan and Piper Jaffray acted as the lead managers on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: OXFD

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

89,970,926
  • $16.15 ▲ 0.12%
77,131,582
  • $58.94 ▼ 1.31%
67,336,935
  • $26.56 ▲ 1.68%
48,814,124
  • $86.20 ▲ 0.02%
47,526,126
  • $23.21 ▲ 0.78%
44,660,424
  • $23.91 ▲ 6.36%
38,799,699
  • $4.289 ▲ 4.36%
36,199,890
  • $40.01 ▼ 0.97%
As of 4/17/2014, 04:07 PM